IL283706A - Pharmacotherapeutic agents and their use as inhibitors of ubiquitin-specific protease 19 - Google Patents

Pharmacotherapeutic agents and their use as inhibitors of ubiquitin-specific protease 19

Info

Publication number
IL283706A
IL283706A IL283706A IL28370621A IL283706A IL 283706 A IL283706 A IL 283706A IL 283706 A IL283706 A IL 283706A IL 28370621 A IL28370621 A IL 28370621A IL 283706 A IL283706 A IL 283706A
Authority
IL
Israel
Prior art keywords
usp19
inhibitors
pharmaceutical compounds
specific protease
ubiquitin specific
Prior art date
Application number
IL283706A
Other languages
English (en)
Hebrew (he)
Inventor
James Samuel Shane Rountree
Steven Kristopher Whitehead
Adam Piotr Treder
Lauren Emma Proctor
Steven David Shepherd
Frank Burkamp
Joana Rita Castro Costa
Colin O'dowd
Timothy Harrison
Matthew Duncan Helm
Ewelina Rozyka
Aaron Cranston
Xavier Jacq
Original Assignee
Almac Discovery Ltd
James Samuel Shane Rountree
Steven Kristopher Whitehead
Adam Piotr Treder
Lauren Emma Proctor
Steven David Shepherd
Frank Burkamp
Joana Rita Castro Costa
Odowd Colin
Timothy Harrison
Matthew Duncan Helm
Ewelina Rozyka
Aaron Cranston
Xavier Jacq
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from GBGB1819937.2A external-priority patent/GB201819937D0/en
Priority claimed from GBGB1904339.7A external-priority patent/GB201904339D0/en
Priority claimed from GBGB1911311.7A external-priority patent/GB201911311D0/en
Application filed by Almac Discovery Ltd, James Samuel Shane Rountree, Steven Kristopher Whitehead, Adam Piotr Treder, Lauren Emma Proctor, Steven David Shepherd, Frank Burkamp, Joana Rita Castro Costa, Odowd Colin, Timothy Harrison, Matthew Duncan Helm, Ewelina Rozyka, Aaron Cranston, Xavier Jacq filed Critical Almac Discovery Ltd
Publication of IL283706A publication Critical patent/IL283706A/en

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/06—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/4965—Non-condensed pyrazines
    • A61K31/497—Non-condensed pyrazines containing further heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/535—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines
    • A61K31/5375—1,4-Oxazines, e.g. morpholine
    • A61K31/5377—1,4-Oxazines, e.g. morpholine not condensed and containing further heterocyclic rings, e.g. timolol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P21/00—Drugs for disorders of the muscular or neuromuscular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/04—Anorexiants; Antiobesity agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
    • C07D405/14—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D413/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings
    • C07D413/06—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D413/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
    • C07D417/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
    • C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
    • C07D471/04—Ortho-condensed systems
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
    • C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
    • C07D487/04—Ortho-condensed systems
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D491/00—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00
    • C07D491/02—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00 in which the condensed system contains two hetero rings
    • C07D491/04—Ortho-condensed systems
    • C07D491/044—Ortho-condensed systems with only one oxygen atom as ring hetero atom in the oxygen-containing ring
    • C07D491/048—Ortho-condensed systems with only one oxygen atom as ring hetero atom in the oxygen-containing ring the oxygen-containing ring being five-membered
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D495/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having sulfur atoms as the only ring hetero atoms
    • C07D495/02—Heterocyclic compounds containing in the condensed system at least one hetero ring having sulfur atoms as the only ring hetero atoms in which the condensed system contains two hetero rings
    • C07D495/04—Ortho-condensed systems
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D498/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D498/02—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and oxygen atoms as the only ring hetero atoms in which the condensed system contains two hetero rings
    • C07D498/04—Ortho-condensed systems

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Diabetes (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Obesity (AREA)
  • Hematology (AREA)
  • Child & Adolescent Psychology (AREA)
  • Emergency Medicine (AREA)
  • Endocrinology (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Neurology (AREA)
  • Epidemiology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Heterocyclic Carbon Compounds Containing A Hetero Ring Having Oxygen Or Sulfur (AREA)
  • Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
IL283706A 2018-12-06 2021-06-03 Pharmacotherapeutic agents and their use as inhibitors of ubiquitin-specific protease 19 IL283706A (en)

Applications Claiming Priority (4)

Application Number Priority Date Filing Date Title
GBGB1819937.2A GB201819937D0 (en) 2018-12-06 2018-12-06 Pharmaceutical compounds
GBGB1904339.7A GB201904339D0 (en) 2019-03-28 2019-03-28 Pharmaceutical compounds
GBGB1911311.7A GB201911311D0 (en) 2019-08-07 2019-08-07 Pharmaceutical compounds
PCT/GB2019/053457 WO2020115501A1 (en) 2018-12-06 2019-12-06 Pharmaceutical compounds and their use as inhibitors of ubiquitin specific protease 19 (usp19)

Publications (1)

Publication Number Publication Date
IL283706A true IL283706A (en) 2021-07-29

Family

ID=68887435

Family Applications (1)

Application Number Title Priority Date Filing Date
IL283706A IL283706A (en) 2018-12-06 2021-06-03 Pharmacotherapeutic agents and their use as inhibitors of ubiquitin-specific protease 19

Country Status (12)

Country Link
US (1) US20220033397A1 (cg-RX-API-DMAC7.html)
EP (1) EP3890829A1 (cg-RX-API-DMAC7.html)
JP (1) JP2022512128A (cg-RX-API-DMAC7.html)
KR (1) KR20210102285A (cg-RX-API-DMAC7.html)
CN (1) CN113365696A (cg-RX-API-DMAC7.html)
AU (1) AU2019393162A1 (cg-RX-API-DMAC7.html)
BR (1) BR112021010644A2 (cg-RX-API-DMAC7.html)
CA (1) CA3121376A1 (cg-RX-API-DMAC7.html)
IL (1) IL283706A (cg-RX-API-DMAC7.html)
MX (1) MX2021006540A (cg-RX-API-DMAC7.html)
SG (1) SG11202105913RA (cg-RX-API-DMAC7.html)
WO (1) WO2020115501A1 (cg-RX-API-DMAC7.html)

Families Citing this family (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB201801562D0 (en) * 2018-01-31 2018-03-14 Almac Diagnostics Ltd Pharmaceutical compounds
GB202104097D0 (en) * 2021-03-24 2021-05-05 Almac Discovery Ltd Pharmaceutical compounds
GB202311227D0 (en) 2023-07-21 2023-09-06 Almac Discovery Ltd Pharmaceutical compounds

Family Cites Families (12)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AUPO111096A0 (en) * 1996-07-18 1996-08-08 Fujisawa Pharmaceutical Co., Ltd. New compound
US7217710B2 (en) 2001-10-02 2007-05-15 Smithkline Beecham Corporation Substituted pyrazolopyrimidines
EP2565186A1 (en) * 2011-09-02 2013-03-06 Hybrigenics S.A. Selective and reversible inhibitors of ubiquitin specific protease 7
TWI698436B (zh) * 2014-12-30 2020-07-11 美商佛瑪治療公司 作為泛素特異性蛋白酶7抑制劑之吡咯并及吡唑并嘧啶
MA41291A (fr) * 2014-12-30 2017-11-07 Forma Therapeutics Inc Dérivés de la pyrrolotriazinone et de l'imidazotriazinone en tant qu'inhibiteurs de la protéase spécifique de l'ubiquitine n° 7 (usp7) pour le traitement d'un cancer
HK1248221A1 (zh) * 2015-02-05 2018-10-12 Forma Therapeutics, Inc. 异噻唑啉酮类,吡唑并嘧啶酮类和吡咯并嘧啶酮作为泛蛋白特异性蛋白酶7抑制剂
EP3253765A1 (en) * 2015-02-05 2017-12-13 Forma Therapeutics, Inc. Thienopyrimidinones as ubiquitin-specific protease 7 inhibitors
EP3253738A1 (en) * 2015-02-05 2017-12-13 Forma Therapeutics, Inc. Quinazolinones and azaquinazolinones as ubiquitin-specific protease 7 inhibitors
FR3052452B1 (fr) * 2016-06-10 2018-06-22 Les Laboratoires Servier Nouveaux derives de piperidinyle, leur procede de preparation et les compositions pharmaceutiques qui les contiennent
PL3468971T3 (pl) * 2016-06-10 2020-08-10 Les Laboratoires Servier Nowe pochodne (hetero)arylo-piperydynylowe, sposoby ich wytwarzania oraz zawierające je kompozycje
GB201612938D0 (en) * 2016-07-26 2016-09-07 Almac Discovery Ltd Pharmaceutical compounds
GB201801562D0 (en) * 2018-01-31 2018-03-14 Almac Diagnostics Ltd Pharmaceutical compounds

Also Published As

Publication number Publication date
US20220033397A1 (en) 2022-02-03
BR112021010644A2 (pt) 2021-09-28
KR20210102285A (ko) 2021-08-19
WO2020115501A1 (en) 2020-06-11
MX2021006540A (es) 2021-07-07
CN113365696A (zh) 2021-09-07
CA3121376A1 (en) 2020-06-11
JP2022512128A (ja) 2022-02-02
AU2019393162A1 (en) 2021-06-17
SG11202105913RA (en) 2021-07-29
EP3890829A1 (en) 2021-10-13

Similar Documents

Publication Publication Date Title
ZA202004025B (en) Novel compounds and pharmaceutical compositions thereof for the treatment of diseases
IL279397A (en) New compounds and their pharmaceutical preparations for the treatment of diseases
ZA202004909B (en) 4-hydroxypiperidine derivatives and their use as inhibitors of ubiquitin specific protease 19 (usp19)
EP3116859A4 (en) Novel compounds as histone deacetylase 6 inhibitors and pharmaceutical compositions comprising the same
MX382624B (es) Compuestos farmacéuticos.
EP3749365A4 (en) PEPTIDY INHIBITORS OF THE CALCINEURIN-NFAT INTERACTION
IL280770A (en) Diazabicyclooctanones as inhibitors of serine beta-lactamases
DK3911304T3 (da) Tabletformuleringer med modificeret frigivelse indeholdende phosphodiesterase-hæmmere
IL281357B (en) cd73 inhibitors and their pharmaceutical uses
SG11202102479TA (en) Uses of plasminogen activator inhibitor 1 (pai-1) inhibitors
PH12018500504A1 (en) Compounds useful for inhibiting ror-gamma-t
MX2021003643A (es) Derivados de terpenoides y usos de los mismos.
IL274737A (en) Novel piperidinyls as inhibitors of ubiquitin-specific protease 7
IL282591A (en) Aminopeptidase a inhibitors and pharmaceutical compositions comprising the same
IL307163A (en) Pharmaceutical donkeys as inhibitors of ubiquitin-specific protease 19
HK40052013A (en) Pharmaceutical compounds and their use as inhibitors of ubiquitin specific protease 19 (usp19)
EP3646864A4 (en) PEMAFIBRATE MEDICINAL PRODUCT
EP3844289A4 (en) COMPOSITION AND USE OF CAS PROTEIN INHIBITORS
TR201620309A2 (tr) Metformi̇n hi̇droklori̇t ve pi̇ogli̇tazon hi̇droklori̇ti̇n farmasöti̇k bi̇leşi̇mleri̇
HK40038552A (en) New piperidinyl derivatives as inhibitors of ubiquitin specific protease 7
ZA202005459B (en) Methods of use and pharmaceutical compositions of a selective syk inhibitor
HK40078214A (en) Pharmaceutical compounds and methods of use
HK40058373A (en) Uses of plasminogen activator inhibitor 1 (pai-1) inhibitors
HK40042107A (en) Peptidyl inhibitors of calcineurin-nfat interaction
HK40041793A (en) Methods of use and pharmaceutical compositions of a selective syk inhibitor